

1/12




FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 6

FIG. 5

TIME POST TUMOR TRANSPLANTATION
[DAYS]



INHIBITION OF ANTI-MUC1 ANTIBODY POSITIVE
PATIENT SAMPLES WITH MUC1-DERIVED PEPTIDES
UNTREATED SAMPLES (FREE ANTIBODIES)




FIG. 7A-1




FIG. 7A-2

5/12




FIG. 7A-3




FIG. 7A-4

6/12




FIG. 7A-5




FIG. 7A-6

7/12

Patient KMC




FIG. 7A-7

Assay Controls




FIG. 7A-8




FIG. 7A-9

9/12

INHIBITION OF ANTI-MUC1 ANTIBODY POSITIVE
PATIENT SAMPLES WITH MUC1-DERIVED PEPTIDES
TREATED SAMPLES (FREE AND MUC1-COMPLEXED SAMPLES)




FIG. 7B-1




FIG. 7B-2

10/12




FIG. 7B-3




FIG. 7B-4

11/12

Patient AK




FIG. 7B-5

Patient RAN




FIG. 7B-6

12/12

Patient KMC




FIG. 7B-7




FIG. 7B-8